The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antidiabetic Drug Market Research Report 2025
Synopsis
Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance and β cell dysfunction. the result of. When diabetes patients undergo diet and exercise therapy and diabetes care education, blood glucose control can still not reach the treatment goals, the need for drug treatment-Antidiabetic Drug
The global Antidiabetic Drug market was valued at US$ 44610 million in 2023 and is anticipated to reach US$ 87890 million by 2030, witnessing a CAGR of 10.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antidiabetic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidiabetic Drug.
Report Scope
The Antidiabetic Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antidiabetic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antidiabetic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi-Aventis
Eli Lilly
Oramed
Takeda
Boehringer Ingelheim
Novo Nordisk
Halozyme Therapeutics
Bristol-Myers Squibb
Pfizer
Tonghua Dongbao
Biocon
Wockhardt
Segment by Type
Alpha-Glucosidase Inhibitors
Biguanides, Sulphonylureas
Glp-1 Agonist
Meglitinides
Dpp-4 Inhibitors
Sglt–2
Thiazolodinediones
Segment by Application
Type I Diabetes
Type II Diabetes
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidiabetic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidiabetic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Diabetes mellitus is a kind of chronic comprehensive disease mainly caused by glucose metabolism disorder due to absolute or relative deficiency of insulin or decreased insulin sensitivity of target cells. The occurrence of type 2 diabetes mellitus is a combination of peripheral insulin resistance and β cell dysfunction. the result of. When diabetes patients undergo diet and exercise therapy and diabetes care education, blood glucose control can still not reach the treatment goals, the need for drug treatment-Antidiabetic Drug
The global Antidiabetic Drug market was valued at US$ 44610 million in 2023 and is anticipated to reach US$ 87890 million by 2030, witnessing a CAGR of 10.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antidiabetic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidiabetic Drug.
Report Scope
The Antidiabetic Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antidiabetic Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antidiabetic Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sanofi-Aventis
Eli Lilly
Oramed
Takeda
Boehringer Ingelheim
Novo Nordisk
Halozyme Therapeutics
Bristol-Myers Squibb
Pfizer
Tonghua Dongbao
Biocon
Wockhardt
Segment by Type
Alpha-Glucosidase Inhibitors
Biguanides, Sulphonylureas
Glp-1 Agonist
Meglitinides
Dpp-4 Inhibitors
Sglt–2
Thiazolodinediones
Segment by Application
Type I Diabetes
Type II Diabetes
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidiabetic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidiabetic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antidiabetic Drug Market Overview
1.1 Product Overview and Scope of Antidiabetic Drug
1.2 Antidiabetic Drug Segment by Type
1.2.1 Global Antidiabetic Drug Market Value Comparison by Type (2024-2030)
1.2.2 Alpha-Glucosidase Inhibitors
1.2.3 Biguanides, Sulphonylureas
1.2.4 Glp-1 Agonist
1.2.5 Meglitinides
1.2.6 Dpp-4 Inhibitors
1.2.7 Sglt–2
1.2.8 Thiazolodinediones
1.3 Antidiabetic Drug Segment by Application
1.3.1 Global Antidiabetic Drug Market Value by Application: (2024-2030)
1.3.2 Type I Diabetes
1.3.3 Type II Diabetes
1.4 Global Antidiabetic Drug Market Size Estimates and Forecasts
1.4.1 Global Antidiabetic Drug Revenue 2019-2030
1.4.2 Global Antidiabetic Drug Sales 2019-2030
1.4.3 Global Antidiabetic Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antidiabetic Drug Market Competition by Manufacturers
2.1 Global Antidiabetic Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antidiabetic Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antidiabetic Drug Average Price by Manufacturers (2019-2024)
2.4 Global Antidiabetic Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antidiabetic Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antidiabetic Drug, Product Type & Application
2.7 Antidiabetic Drug Market Competitive Situation and Trends
2.7.1 Antidiabetic Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antidiabetic Drug Players Market Share by Revenue
2.7.3 Global Antidiabetic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidiabetic Drug Retrospective Market Scenario by Region
3.1 Global Antidiabetic Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antidiabetic Drug Global Antidiabetic Drug Sales by Region: 2019-2030
3.2.1 Global Antidiabetic Drug Sales by Region: 2019-2024
3.2.2 Global Antidiabetic Drug Sales by Region: 2025-2030
3.3 Global Antidiabetic Drug Global Antidiabetic Drug Revenue by Region: 2019-2030
3.3.1 Global Antidiabetic Drug Revenue by Region: 2019-2024
3.3.2 Global Antidiabetic Drug Revenue by Region: 2025-2030
3.4 North America Antidiabetic Drug Market Facts & Figures by Country
3.4.1 North America Antidiabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antidiabetic Drug Sales by Country (2019-2030)
3.4.3 North America Antidiabetic Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antidiabetic Drug Market Facts & Figures by Country
3.5.1 Europe Antidiabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antidiabetic Drug Sales by Country (2019-2030)
3.5.3 Europe Antidiabetic Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antidiabetic Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Antidiabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antidiabetic Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Antidiabetic Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Antidiabetic Drug Market Facts & Figures by Country
3.7.1 Latin America Antidiabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antidiabetic Drug Sales by Country (2019-2030)
3.7.3 Latin America Antidiabetic Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antidiabetic Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Antidiabetic Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antidiabetic Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antidiabetic Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Antidiabetic Drug Sales by Type (2019-2030)
4.1.1 Global Antidiabetic Drug Sales by Type (2019-2024)
4.1.2 Global Antidiabetic Drug Sales by Type (2025-2030)
4.1.3 Global Antidiabetic Drug Sales Market Share by Type (2019-2030)
4.2 Global Antidiabetic Drug Revenue by Type (2019-2030)
4.2.1 Global Antidiabetic Drug Revenue by Type (2019-2024)
4.2.2 Global Antidiabetic Drug Revenue by Type (2025-2030)
4.2.3 Global Antidiabetic Drug Revenue Market Share by Type (2019-2030)
4.3 Global Antidiabetic Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antidiabetic Drug Sales by Application (2019-2030)
5.1.1 Global Antidiabetic Drug Sales by Application (2019-2024)
5.1.2 Global Antidiabetic Drug Sales by Application (2025-2030)
5.1.3 Global Antidiabetic Drug Sales Market Share by Application (2019-2030)
5.2 Global Antidiabetic Drug Revenue by Application (2019-2030)
5.2.1 Global Antidiabetic Drug Revenue by Application (2019-2024)
5.2.2 Global Antidiabetic Drug Revenue by Application (2025-2030)
5.2.3 Global Antidiabetic Drug Revenue Market Share by Application (2019-2030)
5.3 Global Antidiabetic Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Sanofi-Aventis
6.1.1 Sanofi-Aventis Corporation Information
6.1.2 Sanofi-Aventis Description and Business Overview
6.1.3 Sanofi-Aventis Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Sanofi-Aventis Antidiabetic Drug Product Portfolio
6.1.5 Sanofi-Aventis Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Corporation Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly Antidiabetic Drug Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Oramed
6.3.1 Oramed Corporation Information
6.3.2 Oramed Description and Business Overview
6.3.3 Oramed Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Oramed Antidiabetic Drug Product Portfolio
6.3.5 Oramed Recent Developments/Updates
6.4 Takeda
6.4.1 Takeda Corporation Information
6.4.2 Takeda Description and Business Overview
6.4.3 Takeda Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Antidiabetic Drug Product Portfolio
6.4.5 Takeda Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Boehringer Ingelheim Antidiabetic Drug Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 Novo Nordisk
6.6.1 Novo Nordisk Corporation Information
6.6.2 Novo Nordisk Description and Business Overview
6.6.3 Novo Nordisk Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Novo Nordisk Antidiabetic Drug Product Portfolio
6.6.5 Novo Nordisk Recent Developments/Updates
6.7 Halozyme Therapeutics
6.6.1 Halozyme Therapeutics Corporation Information
6.6.2 Halozyme Therapeutics Description and Business Overview
6.6.3 Halozyme Therapeutics Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Halozyme Therapeutics Antidiabetic Drug Product Portfolio
6.7.5 Halozyme Therapeutics Recent Developments/Updates
6.8 Bristol-Myers Squibb
6.8.1 Bristol-Myers Squibb Corporation Information
6.8.2 Bristol-Myers Squibb Description and Business Overview
6.8.3 Bristol-Myers Squibb Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Bristol-Myers Squibb Antidiabetic Drug Product Portfolio
6.8.5 Bristol-Myers Squibb Recent Developments/Updates
6.9 Pfizer
6.9.1 Pfizer Corporation Information
6.9.2 Pfizer Description and Business Overview
6.9.3 Pfizer Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Pfizer Antidiabetic Drug Product Portfolio
6.9.5 Pfizer Recent Developments/Updates
6.10 Tonghua Dongbao
6.10.1 Tonghua Dongbao Corporation Information
6.10.2 Tonghua Dongbao Description and Business Overview
6.10.3 Tonghua Dongbao Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Tonghua Dongbao Antidiabetic Drug Product Portfolio
6.10.5 Tonghua Dongbao Recent Developments/Updates
6.11 Biocon
6.11.1 Biocon Corporation Information
6.11.2 Biocon Antidiabetic Drug Description and Business Overview
6.11.3 Biocon Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Biocon Antidiabetic Drug Product Portfolio
6.11.5 Biocon Recent Developments/Updates
6.12 Wockhardt
6.12.1 Wockhardt Corporation Information
6.12.2 Wockhardt Antidiabetic Drug Description and Business Overview
6.12.3 Wockhardt Antidiabetic Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Wockhardt Antidiabetic Drug Product Portfolio
6.12.5 Wockhardt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antidiabetic Drug Industry Chain Analysis
7.2 Antidiabetic Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antidiabetic Drug Production Mode & Process
7.4 Antidiabetic Drug Sales and Marketing
7.4.1 Antidiabetic Drug Sales Channels
7.4.2 Antidiabetic Drug Distributors
7.5 Antidiabetic Drug Customers
8 Antidiabetic Drug Market Dynamics
8.1 Antidiabetic Drug Industry Trends
8.2 Antidiabetic Drug Market Drivers
8.3 Antidiabetic Drug Market Challenges
8.4 Antidiabetic Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
